radionuclide therapy

Open Access
MIRD Pamphlet No. 27: MIRDcell V3, a revised software tool for multicellular dosimetry and bioeffect modeling
Sumudu Katugampola, Jianchao Wang, Alex Rosen and Roger W. Howell

Journal of Nuclear Medicine February 10, 2022, jnumed.121.263253; DOI: https://doi.org/10.2967/jnumed.121.263253
Open Access
Analysis of short term and stable DNA damage in patients with differentiated thyroid cancer treated with ¹³¹I in hypothyroidism or with rhTSH for remnant ablation
Alberto Signore, Giuseppe Campagna, Jessica Marinaccio, Marco de Vitis, Chiara Lauri, Francesco Berardinelli, Anna Tofani, Marco Chianelli, Marina Borro, Giovanna Gentile, Maurizio Simmaco, Francesco Colombini, Anna Giovanetti and Antonella Sgura

Journal of Nuclear Medicine February 3, 2022, jnumed.121.263442; DOI: https://doi.org/10.2967/jnumed.121.263442
Open Access
Synthesis and Preclinical Evaluation of ¹⁷⁷Lu-labeled Radiohybrid PSMA Ligands (rhPSMAs) for Endoradiotherapy of Prostate Cancer
Alexander Wurzer, Jan-Philip Kunert, Sebastian Fischer, Veronika Felber, Roswitha Beck, Francesco De Rose, Calogero D'Alessandria, Wolfgang Andreas Weber and Hans-Jürgen Wester

Journal of Nuclear Medicine January 27, 2022, jnumed.121.263371; DOI: https://doi.org/10.2967/jnumed.121.263371
Open Access
Substitution of L-Trp by α-methyl-L-Trp in ¹⁷⁷Lu-RM2 results in ¹⁷⁷Lu-AMTG, a high affinity GRPR ligand with improved in vivo stability
Thomas Guenther, Sandra Deiser, Veronika Felber, Roswitha Beck and Hans-Juergen Wester

Journal of Nuclear Medicine January 13, 2022, jnumed.121.263323; DOI: https://doi.org/10.2967/jnumed.121.263323
You have access
SIR-Spheres activity measurements reveal systematic miscalibration
Stephen A Graves, Molly Martin, Ashok Tiwari, Michael J Merrick and John J Sunderland

Journal of Nuclear Medicine January 6, 2022, jnumed.121.262650; DOI: https://doi.org/10.2967/jnumed.121.262650
You have access
Targeted Alpha-Emitter Therapy With ²¹²Pb-DOTAMTATE for the Treatment of Metastatic SSTR-Expressing Neuroendocrine Tumors: First-in-Human, Dose-Escalation Clinical Trial
Ebrahim S Delpassand, Izabela Tworowska, Rouzbeh Esfandiari, Julien Torgue, Jason Hurt, Afshin Shafie and Rodolfo Núñez

Journal of Nuclear Medicine January 6, 2022, jnumed.121.263230; DOI: https://doi.org/10.2967/jnumed.121.263230
You have access
Prostate-specific membrane antigen radioligand therapy using ¹⁷⁷Lu-PSMA I&T and ¹⁷⁷Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer: comparison of safety, biodistribution and dosimetry
Christiane Schuchardt, Jingjing Zhang, Harshad R. Kulkarni, Xiaoyuan Chen, Dirk Mueller and Richard P. Baum

Journal of Nuclear Medicine December 9, 2021, jnumed.121.262713; DOI: https://doi.org/10.2967/jnumed.121.262713
You have access
Long-Term Outcomes of Transarterial Radioembolization for Large Single Hepatocellular Carcinoma: A Comparison to Resection
Jihye Kim, Ju Yeon Kim, Jeong-Hoon Lee, Dong Hyun Sinn, Moon Haeng Hur, Ji Hoon Hong, Min Kyung Park, Hee Jin Cho, Na Ryung Choi, Yun Bin Lee, Eun Ju Cho, Su Jong Yu, Yoon Jun Kim, Jin Chul Paeng, Hyo Cheol Kim, Nam-Joon Yi, Kwang-Woong Lee, Kyung-Suk Suh, Dongho Hyun, Jong Man Kim and Jung-Hwan Yoon

Journal of Nuclear Medicine December 9, 2021, jnumed.121.263147; DOI: https://doi.org/10.2967/jnumed.121.263147
You have access
Tumor Response to Radiopharmaceutical Therapies: The Knowns and the Unknowns
George Sgouros, Yuni K. Dewaraja, Freddy Escorcia, Stephen A. Graves, Thomas A. Hope, Amir Iravani, Neeta Pandit-Taskar, Babak Saboury, Sara St. James and Pat B. Zanzonico

Journal of Nuclear Medicine December 1, 2021, 62 (Supplement 3) 12S-22S; DOI: https://doi.org/10.2967/jnumed.121.262750
You have access
Radionuclide Therapy in Prostate Cancer: From Standalone to Combination PSMA Theranostics
Shahneen Sandhu, Christina Guo and Michael S. Hofman

Journal of Nuclear Medicine December 1, 2021, 62 (12) 1660-1668; DOI: https://doi.org/10.2967/jnumed.120.243295

Main menu

User menu

Search

radionuclide therapy

Pages